文献速递炎症性肠病消化道肿瘤与早癌消化内镜

炎症性肠病患者结肠镜后结直肠癌的特征与生存

Characteristics and Survival of Patients With Inflammatory Bowel Disease and Postcolonoscopy Colorectal Cancers.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-05-26

该研究纳入1995至2015年确诊结直肠癌的炎症性肠病患者,主要分析溃疡性结肠炎(UC)患者。在23738例接受结肠镜检查的UC患者中,352例确诊结直肠癌,其中103例(29%)为结肠镜后结直肠癌(PCCRC)。PCCRC较检出癌更常见转移(33% vs 20%)、错配修复缺陷(79% vs 56%)和近端定位(54% vs 40%),但调整后死亡风险无显著差异。

要点

  • UC患者中PCCRC占结直肠癌的29%。
  • PCCRC转移、错配修复缺陷和近端癌比例更高。
  • PCCRC与检出癌的调整后生存无显著差异。

核心结论

  • UC相关PCCRC的特征提示肿瘤生物学是癌变进展的重要因素,但PCCRC预后与检出癌相似。

研究设计与样本

  • 研究识别1995至2015年确诊结直肠癌的炎症性肠病患者,主要分析UC患者。
  • PCCRC定义为结肠镜检查后6至36个月确诊的结直肠癌,检出癌定义为结肠镜检查后6个月内确诊。
  • 在23738例接受结肠镜检查的UC患者中,352例确诊结直肠癌,其中103例(29%)为PCCRC。

主要发现

  • PCCRC较检出癌更常见转移(33% vs 20%;患病率比1.64;95%CI 1.13-2.38)。
  • PCCRC较检出癌更常见错配修复缺陷(79% vs 56%;患病率比1.40;95%CI 1.13-1.72)。
  • PCCRC较检出癌更常见近端定位(54% vs 40%;患病率比1.34;95%CI 1.06-1.69)。
  • UC患者中PCCRC vs 检出癌的1年调整后死亡风险比1.29(95%CI 0.77-2.18),5年为1.24(95%CI 0.86-1.79)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Postcolonoscopy colorectal cancers (PCCRCs) account for up to 50% of colorectal cancers (CRCs) in patients with inflammatory bowel disease (IBD). We investigated characteristics of IBD patients with PCCRC and their survival. METHODS: We identified IBD patients (ulcerative colitis [UC] and Crohn's disease) diagnosed with CRC from 1995 to 2015. We defined PCCRC as diagnosed between 6 and 36 months, and detected CRC (dCRC) as diagnosed within 6 months after colonoscopy. We computed prevalence ratios comparing PCCRC vs dCRC and followed up patients from the diagnosis of PCCRC/dCRC until death, emigration, or study end. Mortality was compared using Cox proportional hazards regression models adjusted for sex, age, year of CRC diagnosis, and stage. The main analyses focused on patients with UC. RESULTS: Among 23,738 UC patients undergoing colonoscopy, we identified 352 patients with CRC, of whom 103 (29%) had PCCRC. Compared with dCRC, PCCRC was associated with a higher prevalence of metastatic cancer (33% vs 20%; prevalence ratio, 1.64; 95% CI, 1.13-2.38), cancers showing mismatch repair deficiency (79% vs 56%; prevalence ratio, 1.40; 95% CI, 1.13-1.72), and proximally located cancers (54% vs 40%; prevalence ratio, 1.34; 95% CI, 1.06-1.69). The 1- and 5-year adjusted hazard ratios of death for PCCRC vs dCRC among UC patients were 1.29 (95% CI, 0.77-2.18) and 1.24 (95% CI, 0.86-1.79), respectively. CONCLUSIONS: The characteristics of UC-related PCCRC suggest tumor biology as an important factor in the progression to cancer. However, the prognosis of PCCRC appears similar to that of dCRC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Troelsen FS, Sørensen HT, Crockett SD, et al. Characteristics and Survival of Patients With Inflammatory Bowel Disease and Postcolonoscopy Colorectal Cancers. Clin Gastroenterol Hepatol. 2021. PMID: 34051380. doi:10.1016/j.cgh.2021.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。